US law and regulations require that unapproved drug products be investigated and ultimately approved in compliance with the Food & Drug Administration's Investigational New Drug Application (IND) requirements. Provectus is currently authorized to test Rose Bengal in our PV-10 and PH-10 formulations in clinical studies following protocols compliant with the IND process. Provectus cautions that it is unlawful and potentially harmful for individuals to attempt to use Rose Bengal for treatment of cancer or dermatologic disorders outside regulated clinical trials.
It is the policy of Provectus to defend its intellectual property and to aggressively pursue infringement or misappropriation of that property.
Provectus Biopharmaceuticals, Inc. does not endorse nor is responsible for the content in any links provided to websites not maintained by Provectus Biopharmaceuticals, Inc. These links are provided merely for the user's convenience.
Occasionally, Provectus Biopharmaceuticals, Inc. may provide information related to medical conditions or their treatment on this website. This information is not meant to be a substitution for consultation with proper medical professionals. You should always consult a physician or medical advisor.
Safe Harbor Statement
Except for historical information, the statements made herein are forward-looking statements involving significant risks and uncertainties. These risks and uncertainties, including those related to the future financial position and business strategy of Provectus, are detailed in the Company's filings with the Securities and Exchange Commission.
This website is produced by Provectus Biopharmaceuticals, Inc. All product names, logos, service marks, and trademarks are protected by the applicable laws. The content is provided for single-user use and may be printed one time for personal use. Further distribution of the information is potentially in violation of copyright laws.